BRPI0514288A - benzamidas substituìdas com triflúor-metila como inibidores de cinases - Google Patents

benzamidas substituìdas com triflúor-metila como inibidores de cinases

Info

Publication number
BRPI0514288A
BRPI0514288A BRPI0514288-1A BRPI0514288A BRPI0514288A BR PI0514288 A BRPI0514288 A BR PI0514288A BR PI0514288 A BRPI0514288 A BR PI0514288A BR PI0514288 A BRPI0514288 A BR PI0514288A
Authority
BR
Brazil
Prior art keywords
compounds
kinase inhibitors
trifluoromethyl substituted
treatment
substituted benzamides
Prior art date
Application number
BRPI0514288-1A
Other languages
English (en)
Inventor
Giorgio Caravatti
Pascal Furet
Patricia Imbach
Georg Martiny-Baron
Lawrence Blas Perez
Tao Sheng
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0514288A publication Critical patent/BRPI0514288A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

BENZAMIDAS SUBSTITUìDAS COM TRIFLúOR-METILA COMO INIBIDORES DE CINASES A invenção refere-se a compostos de benzamidas substituídas com triflúor-metila da fórmula (I), produtos farmacêuticos que compreendem estes compostos, seu uso ou para a fabricação de produtos farmacêuticos, particularmente como inibidores de proteínas cinases e/ou para o tratamento de uma condição, distúrbio ou estado doentio mediado pela atividade de uma proteína cinase, e/ou uma doença proliferativa, métodos de tratamento que compreendem administrar os compostos, especialmente de tratamento terapêutico e profilático, métodos para a fabricação dos compostos e intermediários inusitados, e etapas parciais para sua síntese.
BRPI0514288-1A 2004-08-11 2005-08-10 benzamidas substituìdas com triflúor-metila como inibidores de cinases BRPI0514288A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0417905.7A GB0417905D0 (en) 2004-08-11 2004-08-11 Organic compounds
PCT/EP2005/008695 WO2006015859A1 (en) 2004-08-11 2005-08-10 Trifluoromethyl substituted benzamides as kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0514288A true BRPI0514288A (pt) 2008-06-10

Family

ID=33017336

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514288-1A BRPI0514288A (pt) 2004-08-11 2005-08-10 benzamidas substituìdas com triflúor-metila como inibidores de cinases

Country Status (17)

Country Link
US (2) US20080096883A1 (pt)
EP (1) EP1778640A1 (pt)
JP (1) JP2008509187A (pt)
KR (1) KR20070046851A (pt)
CN (2) CN101039914A (pt)
AU (1) AU2005270313A1 (pt)
BR (1) BRPI0514288A (pt)
CA (1) CA2575316A1 (pt)
EC (1) ECSP077235A (pt)
GB (1) GB0417905D0 (pt)
IL (1) IL181169A0 (pt)
MA (1) MA28822B1 (pt)
MX (1) MX2007001642A (pt)
NO (1) NO20071300L (pt)
RU (1) RU2007108861A (pt)
TN (1) TNSN07048A1 (pt)
WO (1) WO2006015859A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070054916A1 (en) † 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
WO2006118256A1 (ja) * 2005-04-28 2006-11-09 Kyowa Hakko Kogyo Co., Ltd. 2-アミノキナゾリン誘導体
RU2452492C2 (ru) * 2006-04-05 2012-06-10 Новартис Аг КОМБИНАЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ Bcr-Abl/c-Kit/PDGF-R TK, ДЛЯ ЛЕЧЕНИЯ РАКА
EP2043638A2 (en) * 2006-07-13 2009-04-08 Novartis AG Use of trifluoromethyl substituted benzamides in the treatment of neurological disorders
WO2008009078A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US8673929B2 (en) 2006-07-20 2014-03-18 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
AU2007293065B2 (en) * 2006-09-05 2011-08-18 Amgen Inc. Phthalazine, AZA- and diaza-phthalazine compounds and methods of use
EP2117544A4 (en) * 2006-12-19 2010-03-03 Univ Texas BIOMARKER FOR IDENTIFYING REACTIVATION OF STAT3 AFTER INHIBITION OF SRC
CA2673038C (en) * 2006-12-22 2015-12-15 Incyte Corporation Substituted tricyclic heteroaryl compounds as janus kinase inhibitors
WO2008136948A1 (en) * 2007-05-07 2008-11-13 Amgen Inc. Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as p38 modulators, process for their preparation, and their pharmaceutical use
CA2685674C (en) * 2007-05-07 2012-07-17 Amgen Inc. Pyrazolo-pyridinone compounds, process for their preparation, and their pharmaceutical use
WO2009036275A1 (en) * 2007-09-13 2009-03-19 Link Medicine Corporation Treatment of neurodegenerative diseases using indatraline analogs
US8367671B2 (en) * 2008-03-21 2013-02-05 Amgen Inc. Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents
KR20100134693A (ko) 2008-04-23 2010-12-23 교와 핫꼬 기린 가부시키가이샤 2-아미노퀴나졸린 유도체
US8455495B2 (en) 2008-08-29 2013-06-04 Amgen Inc. Pyridazino-pyridinone compounds and methods of use
US8420649B2 (en) 2008-08-29 2013-04-16 Amgen Inc. Pyrido[3,2-d]pyridazine-2(1H)-one compounds as p38 modulators and methods of use thereof
US8497269B2 (en) 2008-10-10 2013-07-30 Amgen Inc. Phthalazine compounds as p38 map kinase modulators and methods of use thereof
US8772481B2 (en) 2008-10-10 2014-07-08 Amgen Inc. Aza- and diaza-phthalazine compounds as P38 map kinase modulators and methods of use thereof
WO2010096395A1 (en) * 2009-02-18 2010-08-26 Syntech Solution Llc Amides as kinase inhibitors
AU2010258800B2 (en) 2009-06-09 2013-10-10 Nantbio, Inc. Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling
JP5785940B2 (ja) 2009-06-09 2015-09-30 アブラクシス バイオサイエンス， エルエルシー トリアジン誘導体類及びそれらの治療応用
KR20120026612A (ko) 2009-06-09 2012-03-19 아브락시스 바이오사이언스, 엘엘씨 벤질 치환 트리아진 유도체와 이들의 치료적 용도
JP2013509444A (ja) * 2009-10-30 2013-03-14 アリアド・ファーマシューティカルズ・インコーポレイテッド がんの治療方法及び治療用組成物
CN102675289B (zh) * 2011-03-18 2014-11-05 浙江大德药业集团有限公司 作为蛋白激酶抑制剂的n-苯基苯甲酰胺衍生物
EP2701507A1 (en) * 2011-04-26 2014-03-05 Merck Sharp & Dohme Corp. Heterocyclic compounds as b-raf inhibitors for treatment of cancer
SI3097102T1 (en) 2015-03-04 2018-02-28 Gilead Sciences, Inc. A TOOL RECEPTOR MODULING 4,6-DIAMINO-PYRIDO (3,2-D) PYRIMIDINE COMPOUNDS
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
US10370342B2 (en) 2016-09-02 2019-08-06 Gilead Sciences, Inc. Toll like receptor modulator compounds
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202115056A (zh) 2019-06-28 2021-04-16 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
CN111904960A (zh) * 2020-05-19 2020-11-10 合肥合源药业有限公司 一种固体分散体及药用组合物
KR102463217B1 (ko) * 2020-07-13 2022-11-07 한국과학기술연구원 단백질 키나아제 저해 활성을 갖는 4-아미노퀴나졸린-2-카복스아미드 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
CN111925331A (zh) * 2020-07-14 2020-11-13 上海毕得医药科技有限公司 一种6-溴酞嗪的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6587829B1 (en) * 1997-07-31 2003-07-01 Schering Corporation Method and apparatus for improving patient compliance with prescriptions
US6523009B1 (en) * 1999-11-06 2003-02-18 Bobbi L. Wilkins Individualized patient electronic medical records system
US20030236682A1 (en) * 1999-11-08 2003-12-25 Heyer Charlette L. Method and system for managing a healthcare network
US6684276B2 (en) * 2001-03-28 2004-01-27 Thomas M. Walker Patient encounter electronic medical record system, method, and computer product
GB0217757D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use

Also Published As

Publication number Publication date
NO20071300L (no) 2007-04-19
EP1778640A1 (en) 2007-05-02
US20060035897A1 (en) 2006-02-16
TNSN07048A1 (en) 2008-06-02
KR20070046851A (ko) 2007-05-03
MX2007001642A (es) 2007-04-10
ECSP077235A (es) 2007-03-29
WO2006015859A1 (en) 2006-02-16
JP2008509187A (ja) 2008-03-27
RU2007108861A (ru) 2008-09-20
IL181169A0 (en) 2007-07-04
MA28822B1 (fr) 2007-08-01
US20080096883A1 (en) 2008-04-24
GB0417905D0 (en) 2004-09-15
CN101696188A (zh) 2010-04-21
CA2575316A1 (en) 2006-02-16
AU2005270313A1 (en) 2006-02-16
CN101039914A (zh) 2007-09-19

Similar Documents

Publication Publication Date Title
BRPI0514288A (pt) benzamidas substituìdas com triflúor-metila como inibidores de cinases
Ludka et al. Involvement of PI3K/Akt/GSK-3β and mTOR in the antidepressant-like effect of atorvastatin in mice
BR112014028841A2 (pt) processo para preparação de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-l-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
BRPI0610850A2 (pt) derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
BRPI0713755A8 (pt) composto ou um sal ou solvato do mesmo, uso do composto ou um sal ou salvato do mesmo, composição farmacêutica,e, processo para a preparação de um composto ou um sal ou solvato do mesmo
BRPI0512974A (pt) novos derivados de hidantoìna para o tratamento de doenças obstrutivas das vias aéreas
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
BR112013010564A8 (pt) compostos heterocíclicos e usos dos mesmos
BRPI0416801A (pt) derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
BR112014009415A2 (pt) inibidores de arginase e suas aplicações terapêuticas
BRPI0507120A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
BRPI0510664B8 (pt) derivados de fenol e tiofenol 3 ou 4-monosubstituído, composição farmacêutica, combinação e uso dos compostos para tratamento de doenças relacionadas ao h3, incluindo transtornos do sistema nervoso central e transtornos inflamatórios
BRPI0518222A (pt) composto, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3 e utilização dos mesmos
BRPI0606313A2 (pt) derivados de 4-(1h-indol-3-il)-pirimidin-2-ilamina, processo para sua preparação e seu uso em terapia
BRPI0409227A (pt) composto, composição farmacêutica, uso de um composto, intermediário, e, processo para a preparação de um composto
BRPI0507198A (pt) derivados de bisariluréia
BRPI0415683A (pt) inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
BRPI0507375A (pt) derivados de 1h-tieno[2,3-c]pirazol úteis como inibidores de quinase
BR112012016330B8 (pt) ativadores de tieno [2, 3-b] piridinadiona de ampk e composição farmacêutica compreendendo os mesmos
BRPI0706992C8 (pt) composto de fórmula (i) e formulação farmacêutica
BR0315580A (pt) Derivados de metileno uréia

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.